Tonix in the News

The Frederick News-Post | Oct 18, 2021

New Infectious Disease Research and Development Center Opens in Frederick

WDVM News | Oct 18, 2021

Tonix Pharmaceuticals comes to Frederick

Bloomberg | Aug 23, 2021

FDA Grants Full Approval of Pfizer-BioNTech Vaccine (Podcast)

Boston Business Journal | Aug 9, 2021

Biopharma company Tonix expanding to New Bedford

Boston Globe | Aug 2, 2021

Talking Points: N.J. biotech plans to manufacture vaccines in new Mass. plant

Baltimore Business Journal | Jul 27, 2021

New Jersey pharma company to purchase Frederick R&D facility

Benzinga | Jul 15, 2021

More Than Vaccines: Tonix Programs Address the Spectrum of Covid-19 Problems from Prevention, to Infection to Post-Viral Syndrome

Technology Networks | Jun 1, 2021

Dr. Seth Lederman discusses T Cell Immunity and COVID-19 on Technology Networks

Bloomberg | May 25, 2021

Dr. Seth Lederman Discusses COVID-19 Vaccine durability and further development on Bloomberg Radio

Bloomberg | Mar 23, 2021

Dr. Seth Lederman interviewed on Nobel Laureate Economist on Vaccine Equity

Benzinga | Mar 19, 2021

Positive Phase 3 Efficacy Data Bolsters Tonix Pharmaceuticals' Expectations For Phase 3 Confirmatory Trial In Fibromyalgia

Benzinga | Feb 2, 2021

Tonix Pharmaceuticals CEO Believes That Additional COVID-19 Vaccine Research Is Still Needed

ABC FOX Montana | Jan 6, 2021

Dr. Seth Lederman interviewed on ABC FOX Montana to discuss highlights of Tonix’s planned vaccine manufacturing facility in Hamilton, MT

Contagion Live | Dec 4, 2020

Dr. Seth Lederman interviewed on Contagion Live to discuss its COVID-19 vaccine in development

Bloomberg | Jun 9, 2020

Dr. Seth Lederman interviewed on Bloomberg Radio to discuss COVID-19 Vaccine development

Technology Networks | Apr 7, 2020

Dr. Seth Lederman’s interview with the Science Writer for Technology Networks

New England Journal of Medicine | Mar 30, 2020

Developing Covid-19 Vaccines at Pandemic Speed

Proactive | Sep 5, 2019

Tonix Pharmaceuticals doses first patient in Phase 1 trial to treat PTSD

Washington Examiner | Jan 1, 2019

Military-related PTSD: Our year to act

Washington Post | Jul 7, 2017

Tonix is enrolling in a Phase 3 study for Fibromyalgia, and Phase 2 studies for Long COVID, Chronic Migraine, and Major Depressive Disorder. Please visit Clinical Trials.

Tonix in the News

New Infectious Disease Research and Development Center Opens in Frederick

Tonix Pharmaceuticals comes to Frederick

FDA Grants Full Approval of Pfizer-BioNTech Vaccine (Podcast)

Biopharma company Tonix expanding to New Bedford

Talking Points: N.J. biotech plans to manufacture vaccines in new Mass. plant

New Jersey pharma company to purchase Frederick R&D facility

More Than Vaccines: Tonix Programs Address the Spectrum of Covid-19 Problems from Prevention, to Infection to Post-Viral Syndrome

Dr. Seth Lederman discusses T Cell Immunity and COVID-19 on Technology Networks

Dr. Seth Lederman Discusses COVID-19 Vaccine durability and further development on Bloomberg Radio

Dr. Seth Lederman interviewed on Nobel Laureate Economist on Vaccine Equity

Positive Phase 3 Efficacy Data Bolsters Tonix Pharmaceuticals' Expectations For Phase 3 Confirmatory Trial In Fibromyalgia

Tonix Pharmaceuticals CEO Believes That Additional COVID-19 Vaccine Research Is Still Needed

Dr. Seth Lederman interviewed on ABC FOX Montana to discuss highlights of Tonix’s planned vaccine manufacturing facility in Hamilton, MT

Dr. Seth Lederman interviewed on Contagion Live to discuss its COVID-19 vaccine in development

Dr. Seth Lederman interviewed on Bloomberg Radio to discuss COVID-19 Vaccine development

Dr. Seth Lederman’s interview with the Science Writer for Technology Networks

Developing Covid-19 Vaccines at Pandemic Speed

Tonix Pharmaceuticals doses first patient in Phase 1 trial to treat PTSD

Military-related PTSD: Our year to act

Scientists synthesize smallpox cousin in ominous breakthrough